Venrock

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Luma, Inc. is a company that specializes in designing and developing technology for managing events. Founded in 2020 and headquartered in Santa Monica, California, Luma offers a platform that facilitates the organization of live virtual events. Its services include ticket sales, membership management, attendance tracking, and analytics, as well as tools for sending invitations and posting stories. The platform caters to professionals by providing them with the necessary tools to host virtual classes and live shows, thereby enhancing their ability to educate and connect with their communities.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Biolux Research develops and distributes innovative orthodontic products aimed at improving dental treatment outcomes. The company is known for its flagship devices, OrthoPulse and OsseoPulse. OrthoPulse utilizes low levels of light energy to stimulate the bone surrounding teeth, which may facilitate faster tooth movement and potentially shorten the duration of orthodontic treatments such as braces or clear aligners. OsseoPulse focuses on bone regeneration, enhancing dental procedures. Founded in 2003, Biolux Research is headquartered in Vancouver, Canada, and is dedicated to making orthodontic treatments less invasive and more comfortable through advanced technologies.

Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed to target only fat cells and not harm the skin or other tissue. The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed to target only fat cells and not harm the skin or other tissue. The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments.

PEAK Surgical is a medical device company based in Palo Alto, California, focused on developing surgical tools that combine the precision of a scalpel with the bleeding control typical of traditional electrosurgery. The company's flagship product, the PEAK Surgery System, includes a range of disposable cutting devices designed to minimize collateral damage during surgical procedures. This innovative system is approved for use in various surgical fields, including general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal, and neurological surgeries in the United States, as well as general surgery in the European Union. PEAK Surgical aims to fill a critical gap in the surgical market by providing enhanced tools for physicians.

Mevion Medical Systems, Inc. develops advanced proton therapy systems for the radiation treatment of cancer patients, serving customers globally. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company was previously known as Still River Systems, Inc. Mevion is recognized as a pioneer in modern proton therapy, with its flagship product, the MEVION S250 Proton Therapy System. This system aims to maintain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating patented technology, Mevion enhances beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment worldwide.

PEAK Surgical is a medical device company based in Palo Alto, California, focused on developing surgical tools that combine the precision of a scalpel with the bleeding control typical of traditional electrosurgery. The company's flagship product, the PEAK Surgery System, includes a range of disposable cutting devices designed to minimize collateral damage during surgical procedures. This innovative system is approved for use in various surgical fields, including general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal, and neurological surgeries in the United States, as well as general surgery in the European Union. PEAK Surgical aims to fill a critical gap in the surgical market by providing enhanced tools for physicians.

AcceLight Networks has unleashed a new class of intelligent optical core aggregation - Photonic Service Switching (PSS). The innovative solutions provided by the PhotoniX family provides switched services to the installed wavelength core, which enables massive scalability with new revenue opportunities.

Princeton Lightwave, Inc. develops Geiger-mode LiDAR technology for detecting and processing photons digitally in real-time. Its portfolio includes GeigerCruizer, a semiconductor-based solution designed for autonomous navigation in the automotive industry; and Geiger-mode camera, a turn-key system that comprises a single-photon imaging sensor in which every pixel provides time-of-flight information with free-running operation and asynchronous timestamp readout, as well as Geiger-mode detectors and components. The company was founded in 2000 and is based in Cranbury, New Jersey. Princeton Lightwave, Inc. is a former subsidiary of Sarnoff Corporation. As of October 27, 2017, Princeton Lightwave, Inc. operates as a subsidiary of Argo AI, LLC.

ThermoSpectra develops, manufactures, and markets precision imaging, inspection, and measurement instrumentation that uses high-speed data acquisition and digital processing technologies. The company is based in Franklin, Massachusetts.